Leukemia Research
Volume 26, Issue 11 , Pages 1043-1046, November 2002

Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis:

Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma

  • Luis Escribano

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jaime Pérez de Oteyza

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • ,
  • Rosa Núñez

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • ,
  • Alberto Orfao

      Affiliations

    • Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain

Received 4 March 2002; accepted 10 April 2002.

Abstract 

In the present paper a case of a 65-year-old man diagnosed as suffering from a lymphoplasmacytic lymphoma, resistant to conventional chemotherapy, associated to a bone marrow (BM) mastocytosis, who was successfully treated with cladribine is reported. In this patient cladribine induced not only clinical remission of the lymphoplasmacytic lymphoma but it was also associated with immunophenotypical changes in the BM mast cells (MCs) compartment. Such changes were consistent with a decrease in the number of phenotypically aberrant (CD2+/CD25++/CD35++/CD69++/CD117++) MCs and the reappearance in the BM of MCs displaying a normal phenotype (CD2−/CD25−/CD35−/CD69+/CD117+++). Despite the potential utility of cladribine in the treatment of mastocytosis, our observations should be considered as preliminary and caution should be taken as regards the exact indications of the use of this purine analog in mastocytosis.

Keywords:  Mastocytosis, Lymphoplasmacytic lymphoma, Treatment, Cladribine, Immunophenotype, Flow cytometry, CD2, CD25

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(02)00073-5

Leukemia Research
Volume 26, Issue 11 , Pages 1043-1046, November 2002

Article Tools

* Image Usage & Resolution